The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Xue Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intelligent Oncology Innovation Center Designated by the Ministry of Education, Chongqing Key Laboratory of Intelligent Oncology for Breast Cancer, C…. Hauptthemen laut MEDLINE: Lipoylation, Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 188 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, Science-Health Joint Medical Scientific Research Project of Chongqing, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intelligent Oncology Innovation Center Designated by the Ministry of Education, Chongqing Key Laboratory of Intelligent Oncology for Breast Cancer, Chongqing University Cancer Hospital, and Chongqing University School o…
Förderung
- Natural Science Foundation of Chongqing Municipality
- Science-Health Joint Medical Scientific Research Project of Chongqing
- National Natural Science Foundation of China
Zitieren
APA
Yang, X., Xu, M., Deng, Z., & Xu, B. (2025). The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101264
Vancouver
Yang X, Xu M, Deng Z, Xu B. The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101264
BibTeX
@article{Yang2025,
author = {Yang, Xue and Xu, Mengke and Deng, Zhiqin and Xu, Bo},
title = {The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101264}
}
EUVIMED